C2 PHARMA, founded in 2014, is a pharmaceutical conglomerate that specializes in the production and distribution of active pharmaceutical ingredients (APIs) and intricate chemical compounds derived from both natural and synthetic sources. Its current API product line encompasses atropine, bimatoprost, brimonidine, cyclopentolate, digoxin, homatropine, latanoprost, pilocarpine, and tropicamide, and has a global reach extending to over 200 pharmaceutical firms in the United States, Western and Eastern Europe, South America, Asia, the Middle East, and Africa. C2 PHARMA also delivers personalized cold-chain logistics solutions through its dedicated subsidiary, Logistics4Pharma (logistics4pharma.com), and provides R&D-scale contract synthesis services, analytical services, phytochemical profiling, and impurities manufacturing via its associate ASM Research Chemicals (asm-research.de). Notably, C2 PHARMA is a significant supporter of the “Partnerships for a Better World” initiative, which ensures the sustainable, traceable, and equitable procurement and harvesting of raw materials for API production, particularly pilocarpine. This initiative sustains over 1,000 families and contributes to the preservation of Brazilian biodiversity.